Bortezomib will boost the stage or effect of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Greater flibanserin adverse consequences could manifest if coadministered with a number of weak CYP3A4 inhibitors. Cure results in peripheral neuropathy (predominantly sensory); having said that, conditions of intense sensory and motor peripheral neur... https://collinzvngx.bloginwi.com/60469817/fascination-about-2